# A Study of IMC-1121B (Ramucirumab) in Colorectal Cancer

> **NCT00862784** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 48 (actual)

## Conditions studied

- Colorectal Carcinoma

## Interventions

- **BIOLOGICAL:** IMC-1121B (ramucirumab)
- **DRUG:** Oxaliplatin
- **DRUG:** Folinic acid
- **DRUG:** 5-FU
- **DRUG:** 5-FU

## Key facts

- **NCT ID:** NCT00862784
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2011-04
- **Final completion:** 2011-08
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2014-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00862784

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00862784, "A Study of IMC-1121B (Ramucirumab) in Colorectal Cancer". Retrieved via AI Analytics 2026-08-19 from https://api.ai-analytics.org/clinical/NCT00862784. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*